Celiac Disease KOL and Management Meetings around the Digestive Disease Week (DDW) conference on Monday, June 4, 2018, in Was...
May 17 2018 - 3:06PM
Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq:INNT), a
clinical stage biotechnology company focused on developing novel
therapeutics for immuno-inflammatory disease, announced that it
plans to host a KOL (Key Opinion Leader) Event and Management
Meetings June 4th while attending the 2018 Digestive Disease Week
(DDW) conference in Washington, D.C.
The event is expected to feature thought leaders discussing
celiac disease drug development led by Joseph Murray, M.D. of the
Mayo Clinic and new basic research around larazotide’s mechanism of
action, pharmacology and dose response led by Anthony Blikslager,
DVM, Ph.D. of North Carolina State University.
|
|
|
|
Event: |
|
|
Innovate KOL Panel |
Date: |
|
|
Monday, June 4,
2018 |
Time: |
|
|
10:00am-11:00am
(Eastern Time) |
Location: |
|
|
Marriott Marquis –
Dogwood Room (Mezzanine Level) |
|
|
|
901 Massachusetts Ave
NW, Washington, D.C. 20001 |
|
|
|
|
Management expects to be in attendance for one-on-one meetings
with the scientific community and other interested parties from 8am
to 5pm on June 4.
To attend the KOL event register on our website. To book an
individual appointment with management, please contact Jennifer K.
Zimmons, Ph.D. at +1 917.214.3514 or
meetings@innovatebiopharma.com.
Innovate intends to make available a live webcast and subsequent
replay of the event on its website. To access the webcast, please
visit the tab in the Events and Presentations section of Innovate’s
investor relations website.
About Innovate Biopharmaceuticals, Inc.
(Nasdaq:INNT): Innovate is a clinical stage biotechnology
company focused on developing novel therapeutics for
immuno-inflammatory diseases. Innovate’s lead drug candidate,
larazotide acetate, has a mechanism of action that renormalizes the
dysfunctional intestinal barrier by decreasing intestinal
permeability and reducing antigen trafficking, such as gliadin
fragments in celiac disease, and bacterial toxins and immunogenic
antigens in NASH. In several diseases, including celiac disease,
NASH, Crohn’s disease, ulcerative colitis, irritable bowel syndrome
(IBS), type 1 diabetes mellitus (T1DM), chronic kidney disease
(CKD), the intestinal barrier is dysfunctional with increased
permeability.
In celiac disease, larazotide is the only drug which has
successfully met the primary endpoint with statistical significance
in a Phase 2b efficacy clinical trial (342 patients). Innovate
successfully completed the End of Phase 2 Meeting with the FDA in
2017 and is preparing to begin Phase 3 registration clinical trials
for celiac disease later in 2018. Larazotide has been exposed to
more than 800 subjects in clinical trials demonstrating a favorable
safety profile comparable to placebo for long-term chronic
administration. Larazotide has received Fast Track designation from
the FDA for celiac disease.
Forward Looking Statements This press release
includes forward-looking statements including, but not limited to,
statements related to our operations and business strategy. The
forward-looking statements contained in this press release are
based on management’s current expectations and are subject to
substantial risks, uncertainty and changes in circumstances. Actual
results may differ materially from those expressed by these
expectations due to risks and uncertainties, including, among
others, those related to our ability to obtain additional capital
on favorable terms to us, or at all, the success, timing and cost
of our drug development program and our ongoing or future clinical
trials, the lengthy and unpredictable nature of the drug approval
process, and our ability to commercialize our product candidates if
approved. These risks and uncertainties include, but may not be
limited to, those described in our Annual Report on Form 10-K filed
with the U.S. Securities and Exchange Commission (the “SEC”) on
March 14, 2018, our Quarterly Report on Form 10-Q filed with the
SEC on May 15, 2018, and in any subsequent filings with the SEC.
Forward-looking statements speak only as of the date of this press
release, and we undertake no obligation to review or update any
forward-looking statement except as may be required by applicable
law.
Innovate Biopharmaceuticals, Inc. Kendyle
Woodard Tel: 919-275-1933 Email:
investor.relations@innovatebiopharma.comwww.innovatebiopharma.com
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From Apr 2023 to Apr 2024